Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04180-6
Abstract: Dear Editor, Chemotherapy-induced nausea and vomiting (CINV) can be associated with reduced quality of life and meaningful complications in multiple myeloma (MM) patients receiving high-dose (HD)-melphalan followed by autologous stem cell transplantation (ASCT) [1, 2].… read more here.
Keywords: chemotherapy; patients receiving; induced nausea; chemotherapy induced ... See more keywords
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-018-4237-7
Abstract: PurposeChemotherapy-induced nausea and vomiting (CINV) continues to be a common side effect of systemic anticancer therapy, decreasing quality of life and increasing resource utilization. The aim of this meta-analysis was to investigate the comparative efficacy… read more here.
Keywords: induced nausea; nausea vomiting; palonosetron; meta analysis ... See more keywords
Impact of body weight-based dosing of palonosetron and ondansetron on postoperative nausea and vomiting following laparoscopic sleeve gastrectomy: a randomized, double-blind study.
Sign Up to like & getrecommendations! Published in 2023 at "Acta chirurgica Belgica"
DOI: 10.1080/00015458.2023.2184939
Abstract: BACKGROUND Postoperative nausea and vomiting (PONV) is a frequent adverse effect following laparoscopic sleeve gastrectomy. Palonosetron with a standard dosing (75 μg) schedule has been questioned due to its low efficiency in obese patients. This study… read more here.
Keywords: palonosetron; laparoscopic sleeve; group; sleeve gastrectomy ... See more keywords
Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) – is there still a role after comparison with palonosetron?
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1342809
Abstract: ABSTRACT Introduction: Chemotherapy-induced nausea and vomiting (CINV) has a negative impact on the lives of subjects receiving chemotherapy. In 2009, the second generation 5-HT3-receptor antagonist, palonosetron, which is longer-acting than granisetron, was shown, as part… read more here.
Keywords: induced nausea; cinv; chemotherapy induced; palonosetron ... See more keywords
Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.
Sign Up to like & getrecommendations! Published in 2021 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyab079
Abstract: BACKGROUND Palonosetron has demonstrated non-inferiority to ondansetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients in the United States and Europe. We conducted a single-arm registration study to evaluate the efficacy, safety and… read more here.
Keywords: chemotherapy; prevention chemotherapy; palonosetron; chemotherapy induced ... See more keywords
Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neurosurgical Anesthesiology"
DOI: 10.1097/ana.0000000000000361
Abstract: Background: Adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) polymorphisms may influence 5-hydroxytryptamine receptor antagonist efficacy by altering their efflux transportation. We evaluated the influence of ABCB1 polymorphisms on the efficacy of ramosetron compared with… read more here.
Keywords: ramosetron palonosetron; surgery; abcb1 polymorphisms; group ... See more keywords
Comparison of palonosetron with combined palonosetron and midazolam for preventing postoperative nausea and vomiting after laparoscopic cholecystectomy
Sign Up to like & getrecommendations! Published in 2021 at "Medicine"
DOI: 10.1097/md.0000000000026997
Abstract: Abstract Background: Postoperative nausea and vomiting (PONV) is an undesirable complication in patients undergoing general anesthesia. Combination therapy via different mechanisms of action for antiemetic prophylaxis has been warranted for effective treatment of PONV. This… read more here.
Keywords: postoperative nausea; combined palonosetron; palonosetron; ponv ... See more keywords
Comparison of Ramosetron with Palonosetron for Prevention of Postoperative Nausea and Vomiting in Patients Receiving Opioid-Based Intravenous Patient-Controlled Analgesia after Gynecological Laparoscopy
Sign Up to like & getrecommendations! Published in 2017 at "BioMed Research International"
DOI: 10.1155/2017/9341738
Abstract: We aimed to compare the effects of ramosetron and palonosetron in the prevention of postoperative nausea and vomiting (PONV) in patients that received opioid-based intravenous patient-controlled analgesia (IV-PCA) after gynecological laparoscopy. We reviewed the electronic… read more here.
Keywords: prevention postoperative; group; gynecological laparoscopy; palonosetron ... See more keywords
Effect of Palonosetron on Physical Symptoms of Surgical Patients: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2022/7474053
Abstract: Background Postoperative nausea and vomiting (PONV) is a typical and unpleasant physical symptom that occurs in patients after surgery, and it may be one of the most challenging elements of the recovery process. PONV can… read more here.
Keywords: palonosetron; meta analysis; surgery; ponv ... See more keywords
Phase III safety evaluation of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.31_suppl.122
Abstract: 122Background: NEPA is an oral fixed combination of the selective NK1 receptor antagonist (RA), netupitant (300 mg), and pharmacologically distinct 5-HT3RA, palonosetron (PALO 0.50 mg), combining two guideline-recommended antiemetic classes in a convenient single capsule.… read more here.
Keywords: combination; multiple cycles; safety; combination fosnetupitant ... See more keywords
Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
Sign Up to like & getrecommendations! Published in 2022 at "Current Cancer Drug Targets"
DOI: 10.2174/1568009622666220513094352
Abstract: Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with many anticancer therapies and can negatively impact patients' quality of life and potentially limit the effectiveness of chemotherapy. Currently, CINV can be prevented… read more here.
Keywords: induced nausea; chemotherapy induced; palonosetron; clinical trials ... See more keywords